KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Total Non-Current Liabilities data on record, last reported at $211.2 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 16.23% year-over-year to $211.2 million; the TTM value through Sep 2025 reached $211.2 million, down 16.23%, while the annual FY2024 figure was $235.9 million, 10.11% down from the prior year.
  • Total Non-Current Liabilities reached $211.2 million in Q3 2025 per NKTR's latest filing, down from $226.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $457.5 million in Q1 2021 and bottomed at $211.2 million in Q3 2025.
  • Average Total Non-Current Liabilities over 5 years is $322.6 million, with a median of $292.2 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 35.86% in 2021, then decreased 27.55% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $410.0 million in 2021, then fell by 17.94% to $336.4 million in 2022, then fell by 22.0% to $262.4 million in 2023, then decreased by 10.11% to $235.9 million in 2024, then dropped by 10.44% to $211.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $211.2 million in Q3 2025, $226.1 million in Q2 2025, and $235.7 million in Q1 2025.